A synthetic peptide from AA 120-170 of human DCTN1 conjugated to an immunogenic carrier protein was used as the antigen. The peptide is homologous in rat and moue.
DCTN1
Reactivity: Human, Mouse, Rat
IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
IHC WB. Use at a concentration of 10-50,micro,g,ml. The optimal dilution should be determined by the end user. Not yet tested in other applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Reconstitute in 500 µl of sterile water. Centrifuge to remove any insoluble material.
Handling Advice
Avoid freeze and thaw cycles.
Storage
4 °C,-20 °C
Storage Comment
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
Expiry Date
12 months
Target
Dynactin 1 (DCTN1)
Alternative Name
DCTN1
Background
FUNCTION: Required for the cytoplasmic dynein-driven retrograde movement of vesicles and organelles along microtubules. Dynein-dynactin interaction is a key component of the mechanism of axonal transport of vesicles and organelles. SUBUNIT: Large macromolecular complex of at least 10 components, p150(glued) binds directly to microtubules and to cytoplasmic dynein. Interacts with the C-terminus of MAPRE1 MAPRE2 and MAPRE3. SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm cytoskeleton. TISSUE SPECIFICITY: Brain. DISEASE: Defects in DCTN1 are the cause of progressive lower motor neuron disease. PLMND is a progressive dominant disease that has no sensory symptoms.